MONDAY, April 11 (HealthDay News) -- Tumor lysate-pulsed dendritic cell (DC) vaccine appears to improve overall survival in patients with glioblastoma, according to research presented at the annual meeting of the American Association of Neurological Surgeons, held from April 9 to 13 in Denver.
In two Phase 1 clinical trials, Isaac Yang, M.D., of the University of California in Los Angeles, and colleagues evaluated the efficacy and safety of DC vaccine therapy among 26 patients with either recurrent or newly diagnosed glioblastoma. The investigators compared patients treated with autologous tumor lysate-pulsed DC vaccine to patients treated with glioma associated-antigen pulsed DC vaccine for time to tumor progression (TTP) and overall survival.
The investigators found that tumor lysate-pulsed DC vaccine treated patients had a significantly longer overall survival compared to patients who received DCs pulsed with specific tumor peptides (35.5 versus 17.5 months). The investigators also found that TTP was 27.4 months in tumor lysate-pulsed DC vaccine treated patients and 11.6 months in patients treated with DCs pulsed with specific tumor peptides; however, this difference was not statistically significant.
"These findings suggest that overall survival may improve in patients treated with tumor lysate-pulsed DC vaccination compared to those who received DCs pulsed with specific glioma-associated antigens. The improvement in overall survival may suggest that tumor lysate DC vaccination has the potential to induce a more heterogeneous and diverse immune response against glioblastoma. Having multiple avenues of attack on gliomas may be more effective than only attacking a few targets on these glioblastomas. Our preliminary results indicate that this type of immunotherapy may offer hope for improved outcome in patients with this devastating brain tumor, and warrants further study on a larger patient group," Yang said in a statement.
Press Release
More Information
